This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Organogenesis Inc.
Organogenesis Inc., a leading regenerative medicine company headquartered in the United States, has been at the forefront of innovation since its founding in 1985. Specialising in advanced wound care and surgical biologics, the company operates primarily in the US, with a growing presence in international markets. Known for its unique portfolio of products, including Apligraf® and Dermagraft®, Organogenesis focuses on providing solutions that promote healing and tissue regeneration. These products stand out due to their ability to harness the body’s natural healing processes, making them essential in the treatment of chronic wounds and surgical applications. With a strong market position, Organogenesis has achieved significant milestones, including numerous FDA approvals and recognition for its commitment to quality and efficacy in regenerative therapies. The company continues to lead the industry, driving advancements that improve patient outcomes and enhance the standard of care.
DitchCarbon Score
How does Organogenesis Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organogenesis Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organogenesis Inc.'s reported carbon emissions
Organogenesis Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported emissions figures. The company is classified as a current subsidiary and does not inherit emissions data from a parent organisation. In terms of climate commitments, there are no documented reduction targets or initiatives such as Science-Based Targets Initiative (SBTi) commitments or other climate pledges. This lack of specific data suggests that Organogenesis Inc. may still be in the early stages of formalising its climate strategy and emissions reporting. As the industry increasingly prioritises sustainability, it is essential for Organogenesis Inc. to establish clear emissions reduction goals and transparent reporting practices to align with global climate standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organogenesis Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
